Department of Neurosurgery, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
Neurosci Lett. 2010 Feb 12;470(2):150-4. doi: 10.1016/j.neulet.2009.12.075. Epub 2010 Jan 5.
Traumatic brain injury is a heterogeneous disease, encompassing a wide range of pathologies. The dopamine agonist lisuride is well established in the therapy of Parkinson's disease. Additionally to its dopaminergic effects it decreases prolactine release, reducing the amount of inflammatory mediators such as TNF-alpha or Il-6. Lisuride has strong binding affinity to serotonergic and histaminergic receptors on neuronal and glial cells leading to scavenging of highly reactive free radicals. Due to its interaction with dopaminergic D2 and D4 receptors as well as 5-HT-1A receptors, NMDA-receptor signaling and glutamate-mediated excitotoxicity can be modulated beneficially. Despite of these promising neuroprotective effects, experimental data scrutinizing the effects of lisuride after acute brain injury are sparse. We therefore investigated the effect of lisuride after controlled cortical impact injury (CCII) in rats. 70 male Sprague-Dawley rats were randomized to lisuride or to placebo treatment by an initial s.c. loading dose (0.3mg/kg BW) and following continuous application (0.5mg/kg/d) by s.c. implanted osmotic pumps. In three experimental groups we determined (sub)acute neuro-physiological changes after trauma. Mean arterial blood pressure, intracranial pressure, and electrical brain activity were monitored acutely for up to 3h after trauma. Brain edema formation was assessed 24h after CCII. Furthermore, contusion volumes were quantified by magnetic resonance tomography and neurological testing was performed for up to 7 days after injury. Associated with the administration of lisuride there was a significant reduction in duration and number of post-traumatic seizures. Despite of a sustained arterial hypotension following the initial bolus administration in the treatment group, contusion volumes and neurological function tests did not differ significantly in comparison to the control group. Overall, lisuride seems to have significant anticonvulsive effects but seems not to influence secondary brain damage in this experimental model.
创伤性脑损伤是一种异质性疾病,包含广泛的病理学。多巴胺激动剂利舒必利在帕金森病的治疗中已得到充分确立。除了其多巴胺能作用外,它还可降低催乳素的释放,减少 TNF-α或 IL-6 等炎症介质的量。利舒必利与神经元和神经胶质细胞上的 5-羟色胺能和组胺能受体具有很强的结合亲和力,导致高度反应性自由基的清除。由于其与多巴胺 D2 和 D4 受体以及 5-HT-1A 受体的相互作用,NMDA 受体信号和谷氨酸介导的兴奋性毒性可以得到有益的调节。尽管具有这些有希望的神经保护作用,但关于利舒必利在急性脑损伤后作用的实验数据仍然很少。因此,我们研究了利舒必利在大鼠控制性皮质撞击伤(CCII)后的作用。70 只雄性 Sprague-Dawley 大鼠通过初始皮下负荷剂量(0.3mg/kg BW)和随后通过皮下植入的渗透泵持续应用(0.5mg/kg/d)随机分为利舒必利或安慰剂治疗组。在三个实验组中,我们确定了创伤后的(亚)急性神经生理变化。平均动脉血压、颅内压和脑电活动在创伤后急性监测长达 3 小时。CCII 后 24 小时评估脑水肿形成。此外,通过磁共振断层扫描定量挫伤体积,并在损伤后长达 7 天进行神经学测试。与利舒必利的给药相关的是创伤后癫痫发作的持续时间和次数明显减少。尽管在治疗组中,初始推注后持续出现动脉低血压,但与对照组相比,挫伤体积和神经功能测试没有明显差异。总的来说,利舒必利似乎具有显著的抗惊厥作用,但在这个实验模型中似乎不会影响继发性脑损伤。